{"transactions":[{"id":1124383,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-06-03T21:01:06.000Z","date":"2025-05-16","kind":"grant","planned":false,"acquired":true,"shares":1032,"price":2.482,"value":2561.424,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 16, 2025, the Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan at a price of $2.482 per share. Such transaction was exempt under both Rule 16b-3(d) and Rule 16b-3(c) of the Securities Exchange Act of 1934, as amended."}],"balance_after":25337,"source":{"system":"sec-edgar","filing":"0001628280-25-029113","document":"wk-form4a_1748984454.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025029113/wk-form4a_1748984454.xml","form_type":"4/A","original_submission_date":"2025-05-20"}},{"id":1140117,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-05-20T20:51:03.000Z","date":"2025-05-16","kind":"purchase","planned":false,"acquired":true,"shares":1032,"price":2.482,"value":2561.424,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On May 16, 2025, the Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan at a price of $2.482 per share."}],"balance_after":25337,"source":{"system":"sec-edgar","filing":"0001628280-25-026864","document":"wk-form4_1747774254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025026864/wk-form4_1747774254.xml","form_type":"4"}},{"id":1266828,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:08:25.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Grant of restricted stock units to the Reporting Person under the Issuer's Amended and Restated 2017 Equity Incentive Plan with each restricted stock unit representing the right to receive one share of common stock on the applicable vesting date. No amount was paid upon the grant of the restricted stock units. The restricted stock units vest in three equal annual installments on February 12, 2026, February 12, 2027 and February 12, 2028, subject to the Reporting Person continuing to provide service as an employee of the Issuer through such date."}],"balance_after":729173,"source":{"system":"sec-edgar","filing":"0001628280-25-005698","document":"wk-form4_1739567298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025005698/wk-form4_1739567298.xml","form_type":"4"}},{"id":1266827,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:08:25.000Z","date":"2024-11-15","kind":"purchase","planned":false,"acquired":true,"shares":13404,"price":0.343,"value":4597.572,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan. Such purchases were inadvertently omitted from previous Form 4 filings and are now being reported."}],"balance_after":129173,"source":{"system":"sec-edgar","filing":"0001628280-25-005698","document":"wk-form4_1739567298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025005698/wk-form4_1739567298.xml","form_type":"4"}},{"id":1266826,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-02-14T21:08:25.000Z","date":"2024-05-17","kind":"purchase","planned":false,"acquired":true,"shares":21646,"price":0.677,"value":14654.342,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person purchased shares of common stock through the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan. Such purchases were inadvertently omitted from previous Form 4 filings and are now being reported."}],"balance_after":115769,"source":{"system":"sec-edgar","filing":"0001628280-25-005698","document":"wk-form4_1739567298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025005698/wk-form4_1739567298.xml","form_type":"4"}},{"id":1294304,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-01-27T23:15:32.000Z","date":"2025-01-24","kind":"sale","planned":false,"acquired":false,"shares":29159,"price":0.4541,"value":13241.1019,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.4475 to $0.47, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":94123,"source":{"system":"sec-edgar","filing":"0001628280-25-002707","document":"wk-form4_1738019726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025002707/wk-form4_1738019726.xml","form_type":"4"}},{"id":1294303,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2025-01-27T23:15:32.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":74773,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurred upon the acceptance by the European Medicines Agency of the Issuer's Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome."}],"balance_after":123282,"source":{"system":"sec-edgar","filing":"0001628280-25-002707","document":"wk-form4_1738019726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025002707/wk-form4_1738019726.xml","form_type":"4"}},{"id":1389170,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-10-08T20:44:32.000Z","date":"2024-10-07","kind":"sale","planned":false,"acquired":false,"shares":11127,"price":0.5847,"value":6505.9569,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"These transactions were made pursuant to a rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.561 to $0.6115, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":48509,"source":{"system":"sec-edgar","filing":"0001628280-24-042544","document":"wk-form4_1728420266.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024042544/wk-form4_1728420266.xml","form_type":"4"}},{"id":1389169,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2024-10-08T20:44:32.000Z","date":"2024-10-04","kind":"grant","planned":false,"acquired":true,"shares":34946,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition."}],"balance_after":59636,"source":{"system":"sec-edgar","filing":"0001628280-24-042544","document":"wk-form4_1728420266.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024042544/wk-form4_1728420266.xml","form_type":"4"}},{"id":1637697,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Appreciation Right","published_at":"2024-02-16T22:09:15.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":523414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Stock Appreciation Right will vest and become exercisable in equal annual installments (rounding down to the nearest whole share, except for the last installment) on the first, second, and third anniversaries of February 13, 2024, subject to the Reporting Person remaining an\nemployee of the Issuer through and including each applicable vesting date."}],"balance_after":523414,"derivative":{"exercise_price":0.921,"expiration_date":"2034-02-13","underlying":"Common Stock","underlying_shares":523414},"source":{"system":"sec-edgar","filing":"0001628280-24-005380","document":"wk-form4_1708121338.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828024005380/wk-form4_1708121338.xml","form_type":"4"}},{"id":1749419,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-11-03T20:39:45.000Z","date":"2023-11-01","kind":"sale","planned":true,"acquired":false,"shares":10257,"price":0.73,"value":7487.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.687 to $0.7927, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F2","text":"Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award"}],"balance_after":24690,"source":{"system":"sec-edgar","filing":"0001628280-23-036756","document":"wk-form4_1699043973.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023036756/wk-form4_1699043973.xml","form_type":"4"}},{"id":1751079,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock","published_at":"2023-11-02T21:00:56.000Z","date":"2023-10-31","kind":"grant","planned":false,"acquired":true,"shares":34947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor."}],"balance_after":34947,"source":{"system":"sec-edgar","filing":"0001628280-23-036466","document":"wk-form4_1698958841.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828023036466/wk-form4_1698958841.xml","form_type":"4"}},{"id":2124224,"issuer":{"id":5638,"kind":"organization","name":"X4 Pharmaceuticals, Inc","symbol":"XFOR"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-11-04T20:18:11.000Z","date":"2022-11-03","kind":"grant","acquired":true,"shares":341000,"price":1.89,"value":644490.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on November 3, 2023, with the remainder vesting in equal installments of 2.0833% of the shares subject to the option each successive month thereafter for a period of 36 months, subject to the Reporting Person continuing to provide services through each such date."}],"balance_after":341000,"derivative":{"exercise_price":1.89,"expiration_date":"2032-11-03","underlying":"Common Stock","underlying_shares":341000},"source":{"system":"sec-edgar","filing":"0001628280-22-028462","document":"wf-form4_166759306432055.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501697/000162828022028462/wf-form4_166759306432055.xml","form_type":"4"}},{"id":3444282,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commerical Officer"}}],"security":"Share Option (right to buy)","published_at":"2019-08-07T23:16:57.000Z","date":"2019-08-05","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests as to 25% of the shares on August 5, 2020 and the remainder vests quarterly thereafter until August 5, 2023."}],"balance_after":25000,"derivative":{"exercise_price":19.48,"expiration_date":"2029-08-05","underlying":"Ordinary Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-19-021293","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924319021293/doc4.xml","form_type":"4"}},{"id":3444281,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commerical Officer"}}],"security":"Ordinary Shares","published_at":"2019-08-07T23:16:57.000Z","date":"2019-08-05","kind":"grant","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of  RSUs. The RSUs vest as to 50% on August 5, 2020 and 50% on August 5, 2021."}],"balance_after":39000,"source":{"system":"sec-edgar","filing":"0000899243-19-021293","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924319021293/doc4.xml","form_type":"4"}},{"id":3444280,"issuer":{"id":4976,"kind":"organization","name":"Wave Life Sciences, Inc.","symbol":"WVE"},"owners":[{"id":78917,"kind":"person","name":"Baldry Mark","position":1,"cik":"0001644137","reported_name":"Baldry Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commerical Officer"}}],"security":"Ordinary Shares","published_at":"2019-08-07T23:16:57.000Z","date":"2019-08-05","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on August 5, 2020 through August 5, 2023."}],"balance_after":35000,"source":{"system":"sec-edgar","filing":"0000899243-19-021293","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631574/000089924319021293/doc4.xml","form_type":"4"}}]}